<DOC>
	<DOCNO>NCT02621242</DOCNO>
	<brief_summary>As explain detail recently publish hypothesis article ( Hladik F. A new hypothesis HIV cure . F1000Research , 4:77 ( 2015 ) ) , investigator hypothesize NRTI drug may reduce likelihood HIV eradication promote survival cell integrate provirus . In study , investigator test whether daily oral use two NTRI drug , tenofovir emtricitabine ( Truvada Pill ) , induces change upper low gut mucosa congruent support hypothesis .</brief_summary>
	<brief_title>Effects Anti-HIV Pill Truvada Gene Transcription Gastrointestinal Tract HIV-uninfected Individuals</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>• HIVnegative Male gender birth Age ≥18 year old Intent initiate PrEP next 12 month . Willingness ability provide inform consent study participation Willingness undergo require study procedure Creatinine clearance &lt; 60mL/min Platelet count normal reference Coagulation ( PT/PTT ) test normal reference Any prior use PrEP Use PEP within 30 day prior study entry Receipt anticoagulant medication ( e.g . warfarin ) . Aspirin allowable . Systemic corticosteroid medication Nonsteroidal antiinflammatory drug ( NSAID ) use &gt; 2 days/week Signs symptom acute HIV infection within 14 day study entry No availability another person drive participant home day entry followup procedure . Plan leave Seattle area subsequent 2.5 month Any condition substance use , opinion study investigator , would interfere study participation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>